Substitution of anticonvulsant drugs.
Changing from branded drugs to generic alternatives, or between different generic formulations, is common practice aiming at reducing health care costs. It has been suggested that antiepileptic drugs (AEDs) should be exempt from substitution because of the potential negative consequences of adverse events and breakthrough seizures. Controlled data are lacking on the risk of substitution. However, retrospective data from large medical claims databases suggest that switching might be associated with increased use of AED and non-AED medications, and health care resources (including hospitalization). In addition, some anecdotal evidence from patients and health care providers' surveys suggest a potentially negative impact of substitution. Well-controlled data are needed to assess the real risk associated with substitution, allowing health care professionals involved in the care of patients with epilepsy to make informed decisions. This paper reviews currently available literature, based on which the authors suggest that the decision to substitute should be made on an individual basis by the physician and an informed patient. Unendorsed or undisclosed substitution at the pharmacy level should be discouraged.
Steinhoff
Bernhard J
BJ
Epilepsy Center, Kehl-Kork, Germany;
Runge
Uwe
U
Witte
Otto W
OW
Stefan
Hermann
H
Hufnagel
Andreas
A
Mayer
Thomas
T
Krämer
Günter
G
Epilepsy Behav. 2008 Jul;13(1):127-30
18406211
Can J Neurol Sci. 2000 Feb;27(1):37-43
10676586
Neurology. 2004 Oct 26;63(8):1494-6
15505173
Epilepsia. 2007 Mar;48(3):464-9
17346246
Epilepsy Behav. 2005 Aug;7(1):98-105
15961350
Pharm Res. 1992 Dec;9(12):1612-6
1488405
Epilepsia. 1996;37 Suppl 2:S1-S3
8641240
Seizure. 2006 Apr;15(3):165-76
16504545
Epilepsy Behav. 2004 Dec;5(6):995-8
15582850
Ann Pharmacother. 1992 Jun;26(6):775-7
1611158
Epilepsy Behav. 2008 Nov;13(4):693-9
18589000
Epilepsia. 2006;47 Suppl 5:16-20
17239100
Clin Ther. 2007 Feb;29(2):334-41
17472825
J Clin Pharmacol. 1986 May-Jun;26(5):309-16
3700686
Epilepsy Behav. 2002 Dec;3(6):522-525
12609245
Ann Pharmacother. 1997 May;31(5):548-52
9161646
Neurology. 2008 May 27;70(22 Pt 2):2179-86
18505997
Epilepsia. 1995 Dec;36(12):1187-94
7489695
Neurology. 1987 Dec;37(12):1885
3120036
Neurology. 1990 Nov;40(11):1641-3
2234417
Seizure. 1996 Mar;5(1):1-5
8777549
Rev Neurol (Paris). 2007 Apr;163(4):455-61
17452947
Epilepsia. 2005;46 Suppl 11:54-61
16393182
Acta Neurol Scand. 2005 May;111(5):291-300
15819708
JAMA. 1987 Sep 4;258(9):1216-7
3626006
Neurology. 2008 Aug 12;71(7):525-30
18695164
Epilepsia. 2003;44 Suppl 6:1-88
12919341
Br J Clin Pract. 1990 Jul;44(7):270-3
2206824
Epilepsy Res. 2002 Nov;52(1):61-9
12445961
Neurology. 1993 Dec;43(12):2696-7
8255480
Pharm Res. 1998 Nov;15(11):1787-91
9834004
Epilepsia. 2009 Mar;50(3):493-500
18616554
Epileptic Disord. 2007 Dec;9(4):465-6
18055310
Neurology. 2007 Apr 17;68(16):1249-50
17438213
Epilepsy Behav. 2009 Jan;14(1):113-7
18768168
J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):688-91
1527539
Lancet Neurol. 2007 May;6(5):465-8
17434101